triptans serotonin num ht num num agonists migraine detailed results methods meta-analysis num trials pubmed ncbi abstract triptans selective serotonin num ht num num agonists effective acute migraine drugs triptans clinically num oral doses making evidence-based selection guidelines triptan trials similar designs facilitating meta-analysis wished provide evidence-based foundation triptans clinical practice review methodological issues surrounding triptan trials asked pharmaceutical companies principal investigators company-independent trials raw patient data double-blind randomized controlled clinical trials oral triptans migraine data cross-checked published presented data calculated summary estimates studies important efficacy tolerability parameters compared direct head-to-head comparator trials num eligible clinical trials num published involving num patients met criteria inclusion results num confidence intervals sumatriptan num mg widely prescribed oral triptan num num num headache response improvement moderate severe mild pain num num num pain free improvement pain num num sustained pain free pain free num headache recurrence rescue medication num post-dose num num consistency response treated attacks placebo-subtracted proportions patients adverse event ae num num central nervous system ae num num chest ae num num num compared data rizatriptan num mg shows efficacy consistency similar tolerability eletriptan num mg shows efficacy similar consistency lower tolerability almotriptan num mg shows similar efficacy num sustained pain-free response consistency tolerability sumatriptan num mg naratriptan num mg eletriptan num mg show lower efficacy tolerability zolmitriptan num mg num mg eletriptan num mg rizatriptan num mg show similar results results num trials directly compared triptans show pattern received data frovatriptan publicly data suggest substantially lower efficacy major methodological issues involve choice primary endpoint consistency multiple attacks evaluate headache recurrence placebo-subtracted proportions control across-study differences difference tolerability safety addition number methodological issues specific direct comparator trials including encapsulation patient selection marketed doses oral triptans effective tolerated differences general small clinically relevant individual patients rizatriptan num mg eletriptan num mg almotriptan num mg provide highest likelihood consistent success sumatriptan features longest clinical experience widest range formulations triptans contra-indicated presence cardiovascular disease 
